title: Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months.
abstract: The feasibility of long-term extended-release naltrexone (XR-NTX) alcohol treatment is unknown. Following an initial 12-week, single-arm, observational trial of XR-NTX plus medical management (MM) in primary care, we offered 48 additional weeks of XR-NTX treatment (12 additional monthly injections) in two public primary care clinics as a naturalistic extension study. Of 65 alcohol dependent adults initiating XR-NTX treatment, 40 (62%) completed the initial 12-week XR-NTX observational trial, and 19 (29%) continued treatment for a median of 38 weeks total (range, 16-72 weeks; median 8 total XR-NTX injections). Among active extension phase participants, self-reported rates of drinking days (vs. last 30 days pre-treatment baseline) were low: median 0.2 vs. 6.0 drinks per day; 82 vs. 38% days abstinent; 11 vs. 61% heavy drinking days. Long-term XR-NTX treatment in a primary care MM model was feasible and may promote lasting drinking reductions or alcohol abstinence (clinical trial: NCT00620750).
authors.affiliation: New York University School of Medicine, NY, USA. joshua.lee@med.nyu.edu
authors.forename: Joshua D
authors.initials: JD
authors.lastname: Lee
authors.forename: Ellie
authors.initials: E
authors.lastname: Grossman
authors.forename: Laura
authors.initials: L
authors.lastname: Huben
authors.forename: Marc
authors.initials: M
authors.lastname: Manseau
authors.forename: Jennifer
authors.initials: J
authors.lastname: McNeely
authors.forename: John
authors.initials: J
authors.lastname: Rotrosen
authors.forename: David
authors.initials: D
authors.lastname: Stevens
authors.forename: Marc N
authors.initials: MN
authors.lastname: Gourevitch
mesh_terms: D000328:Adult; D000428:Alcohol Drinking / Q000517:prevention & control*; D000437:Alcoholism / Q000534:rehabilitation*; D003692:Delayed-Action Preparations; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000008:administration & dosage*; D009292:Narcotic Antagonists / Q000008:administration & dosage*; D011320:Primary Health Care / Q000379:methods; D013695:Temperance; D013997:Time Factors
chemical_list: D003692:Delayed-Action Preparations; D009292:Narcotic Antagonists; D009271:Naltrexone